Year All202320222021202020192018 March 22, 2023 Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing March 16, 2023 Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial March 9, 2023 Oculis to Present at BioCapital Europe March 3, 2023 Oculis Announces US Public Listing on NASDAQ January 31, 2023 Oculis CEO Riad Sherif MD to Participate in Glaucoma 360 New Horizons Forum January 5, 2023 Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in Diabetic Macular Edema (DME)
March 22, 2023 Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
January 5, 2023 Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in Diabetic Macular Edema (DME)
